HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Methotrexate (Mexate)

Subscribe to New Research on Methotrexate

An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.

Also Known As:

Mexate; Methotrexate Hydrate; Methotrexate, (D)-Isomer; Methotrexate, (DL)-Isomer; Methotrexate, Dicesium Salt; Methotrexate, Disodium Salt; Methotrexate, Sodium Salt; Dicesium Salt Methotrexate; Disodium Salt Methotrexate; Hydrate, Methotrexate; Sodium Salt Methotrexate; Amethopterin; L-Glutamic acid, N-(4-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-

Networked: 15850 relevant articles (1641 outcomes, 2464 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- 2-Ring Heterocyclic Compounds
  - Pteridines: 40
    - Pterins: 52
      - Aminopterin: 222
        Methotrexate: 15850
        CARE protocol: 121
        Regimen B: 97
        CMF regimen: 39
        methotrexate polyglutamate: 38
        CMFVP protocol: 36
        7-hydroxymethotrexate: 33
        PROMACE-CytaBOM protocol: 33
        LSA2-L2 protocol: 29
        M-VAC protocol: 28
        methotrexate-serum albumin: 16
        MACOP-B regimen: 13
        AMF protocol: 9
        N-(1-((2,4-diamino-6-pteridinyl)methyl)-3,4-dihydro -2H-1,4-benzothiazine-7-carbonyl)-L-2-aminoadipic acid: 9
        CMF protocol: 8
        fluoresceinated methotrexate: 8
        MACHO protocol: 7
        MP regimen: 7
        T7 protocol: 7
        ANAVACYM protocol: 6
        MDC protocol: 6
        BFM 78 protocol: 5
        hexa CAF protocol: 5
        CMFPT protocol: 4
        LMB89 protocol: 4
        MAC combination: 4
        MACOP-B protocol: 4
        CMF-B protocol: 3
        COMP protocol: 3
        MEA regimen: 3
        methotrexate-alpha-phenylalanine: 3
        methotrexate-gamma-1,2-dimyristoylphosphatidylethanolamine: 3
        New York protocol: 3
        VBM protocol: 3
        3',5'-dichloromethotrexate: 2
        CCG-141 protocol: 2
        CMV regimen: 2
        dextran T70-methotrexate conjugate: 2
        EMA-CO protocol: 2
        HELP protocol: 2
        MATILDE regimen: 2
        methotrexate-gamma-aspartate: 2
        MMM protocol 2: 2
        PBMF protocol: 2
        tetrahydromethotrexate: 2
        VMP protocol: 2
        5-deazamethotrexate: 1
        AIEOP acute lymphoblastic leukemia protocol: 1
        AWO54: 1
        biotin-SS-methotrexate: 1
        BMFt protocol: 1
        BOMES protocol: 1
        BOP-CISCA-POMB-ACE regimen: 1
        C'MP protocol: 1
        CAM combination: 1
        CAMBO-VIP protocol: 1
        CAMP protocol: 1
        CMED protocol: 1
        CNR-NEO 2 protocol: 1
        COMPA regimen: 1
        COSS-86 protocol: 1
        DTPA-methotrexate: 1
        EMB protocol: 1
        FEMTX-P protocol: 1
        gamma-tert-butyl methotrexate: 1
        L-6 protocol: 1
        LNH87-2 protocol: 1
        M-BACOD protocol: 1
        M-VEC protocol: 1
        MCNO regimen: 1
        MEC protocol 1: 1
        methotrexate bisphosphonate: 1
        MFL protocol: 1
        N,N,O,O-tetrakis(tert-butyldimethylsilyl)methotrexate: 1
        NSC-98579: 1
        OS 87 protocol: 1
        PRIME protocol: 1
        ProMACE-MOPP protocol: 1
        protocol 8001: 1
        SIOP-II protocol: 1
        Stanford University protocol: 1
        T-6 protocol: 1
        T-8801 protocol: 1
        TNP 351: 1
        VIM-Bleo protocol: 1
        VPC regimen: 1
        (COMPADRI)-III protocol
        (N-(4-amino-4-deoxy-N(10)-methylpteroyl)amino)-3-chloro-4,5-dihydro-5-isoxazoleacetic acid
        06-Paris-LA-66 protocol
        10-ethylaminopterin
        3',5'-difluoromethotrexate
        3'-chloromethotrexate
        3M protocol
        4-(N-((2,4-diamino-6-pteridinyl)methyl)amino)benzoic acid
        4-amino-10-methylpteroylhexa-gamma-glutamic acid
        5-hexadecyl methotrexate
        5-monobutyl methotrexate
        7-hydroxydichloromethotrexate
        A-VBM-FH6 protocol
        AAAP protocol
        ACFM protocol

Experts

1.	Emery, Paul: 56 articles (01/2016 - 02/2002)
2.	van der Heijde, Désirée: 33 articles (01/2016 - 01/2003)
3.	Pui, Ching-Hon: 33 articles (05/2015 - 07/2002)
4.	Takeuchi, Tsutomu: 30 articles (01/2016 - 12/2004)
5.	Smolen, Josef S: 30 articles (08/2015 - 10/2004)
6.	Genovese, Mark C: 29 articles (01/2016 - 06/2002)
7.	Keystone, Edward C: 29 articles (02/2015 - 06/2002)
8.	Moreland, Larry W: 26 articles (12/2014 - 03/2002)
9.	Weinblatt, Michael E: 25 articles (10/2015 - 03/2002)
10.	Kremer, Joel M: 24 articles (12/2015 - 11/2002)

Related Diseases

1.	Rheumatoid Arthritis 01/01/1994 - "Early placebo-controlled trials demonstrated that weekly low dosage methotrexate produced early symptomatic improvement in most rheumatoid arthritis patients. " 04/01/2004 - "(1) There is no consensus on the best treatment option for rheumatoid arthritis when a first-line agent fails (most often methotrexate). " 10/01/2013 - "The findings of this systematic review with meta-analysis indicate that tofacitinib monotherapy or with background methotrexate provides early statistically significant and clinically important improvement in rheumatoid arthritis symptoms and has an acceptable safety profile comparable to that of placebo. " 06/01/2003 - "Methotrexate has proven to be effective in treating rheumatoid arthritis (RA), and is believed to be nononcogenic in the low weekly dose typically employed in the patients with RA. " 11/01/1997 - "Because of methotrexate's well-documented efficacy in the treatment of rheumatoid arthritis, it is important that we understand the mechanism of action of this drug. "
2.	Psoriasis (Pustulosis Palmaris et Plantaris) 05/01/2012 - "While methotrexate is the most frequently used systemic treatment for psoriasis, its efficacy for psoriasiform lesions related to anti-TNF therapy remains unknown. " 01/01/2009 - "Methotrexate is the best treatment for severe psoriasis. " 01/01/2006 - "Methotrexate appears to be the most cost-effective agent for the treatment of severe psoriasis. " 08/01/2007 - "Methotrexate is the gold standard therapy for moderate to severe psoriasis, but there is marked interpersonal variation in its efficacy and toxicity. " 10/01/2004 - "Methotrexate 0.25% in a hydrophilic gel is well tolerated but is not very effective in controlling the lesions of psoriasis on the palms and soles. "
3.	Neoplasms (Cancer) 05/01/2006 - "Methotrexate(MTX) is one of the most important and frequently used drugs in cancer therapy, but the efficacy of this drug is often compromised by the development of resistance in cancer cells. " 01/01/2014 - "The clinical efficacy of conventional chemotherapeutic agent, methotrexate (MTX), can be limited by its very short plasma half-life, the drug resistance, and the high dosage required for cancer cell suppression. " 05/15/1987 - "Our results suggest that an analog which could be effectively transported by the low-affinity/high-capacity route may be useful in the treatment of tumors resistant to methotrexate due to a defective high-affinity/low capacity influx system. " 07/01/1989 - "This preliminary study demonstrates that anal injection of methotrexate is effective in the treatment of advanced cancer. " 07/01/2014 - "Methotrexate (MTX) is widely used for the treatment of many types of cancer. "
4.	Lymphoma (Lymphomas) 01/01/2014 - "Methotrexate (MTX) is the single most effective agent for the treatment of primary central nervous system lymphoma. " 01/01/2008 - "Methotrexate (Mtx) is highly effective in lymphomas and crosses the blood-brain barrier. " 08/01/2002 - "Spontaneous complete remission of the lymphoma was achieved 14 months after withdrawing immune suppression with methotrexate." 07/01/2010 - "This study analyzed retrospectively the clinical efficacy of combined therapy consisting of high-dose methotrexate (MTX), administered at a dose of 4 g/m2 every 2 weeks (maximum of 4 courses), followed by whole-brain irradiation for newly diagnosed primary central nervous system lymphoma (PCNSL) patients. " 06/01/2015 - "Stereotactic radiosurgery in combination with up-front high-dose methotrexate as a first-line treatment for newly diagnosed primary central nervous system lymphoma."
5.	Crohn Disease (Crohn's Disease) 06/01/1996 - "Methotrexate appears effective in most patients with refractory Crohn's disease and its short-term toxicity is acceptable, but the long-term benefit seems more limited." 05/01/2009 - "Methotrexate is beneficial in maintaining remission and steroid-sparing treatment in children with Crohn disease following failure of thiopurine therapy." 01/01/2009 - "A pooled analysis (n = 98) including one high quality trail (n = 76) showed that intramuscular methotrexate (15 mg/week) was significantly more effective than placebo for maintenance of remission in Crohn's disease (OR 3.11; 95% CI 1.31 to 7.41; P = 0.01). " 01/01/2014 - "Large-scale studies of methotrexate given orally at higher doses for maintenance of remission in Crohn's disease may provide stronger evidence for the use of methotrexate in this manner." 01/01/2014 - "Moderate quality evidence indicates that intramuscular methotrexate at a dose of 15 mg/week is superior to placebo for maintenance of remission in Crohn's disease. "

Related Drugs and Biologics

1.	Cyclophosphamide (Cytoxan)
2.	Doxorubicin (Adriamycin)
3.	Fluorouracil (Carac)
4.	Cyclosporine (Ciclosporin)
5.	Cisplatin (Platino)
6.	Vincristine (Oncovin)
7.	infliximab (Remicade)
8.	TNFR-Fc fusion protein (etanercept)
9.	Vinblastine (Vinblastine Sulfate)
10.	Azathioprine (Imuran)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Radiotherapy
4.	Remission Induction
5.	Adjuvant Chemotherapy